ARTV
NASDAQArtiva Biotherapeutics Inc.
$10.34-0.94 (-8.29%)
News25/Ratings7
Price$10.34+5.55 (+116.09%)
2026-01-212026-04-24
News · 26 weeks38-80%
2025-11-022026-04-26
Mix1990d
- Insider9(47%)
- SEC Filings5(26%)
- Other3(16%)
- Leadership2(11%)
Latest news
25 items- PRArtiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceSAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a panel as well as a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 2:15 p.m. EDT. To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva's website. The archived audio webcast will remain available for replay on Artiva's w
- INSIDERChief Financial Officer Huston Thad Allen was granted 220,000 shares (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- SECSEC Form S-8 filed by Artiva Biotherapeutics Inc.S-8 - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
- SECSEC Form 10-K filed by Artiva Biotherapeutics Inc.10-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
- SECArtiva Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
- PRArtiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business HighlightsInitial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal trial design for AlloNK expected in first half of 2026 Strengthened board and executive leadership with deep immunology, commercial and financial expertise Robust balance sheet with cash, cash equivalents and investments of $108.0 million as of December 31, 2025, expected to fund operations into Q2 2027 SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessib
- PRArtiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceSAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026, at 1:10 p.m. EST, in Boston, MA. Members of the Artiva management team will also be available to participate in meetings with investors who are registered to attend the conference. To access the audio webcast and subsequent archived recording of this and other company present
- INSIDERSEC Form 3 filed by new insider Huston Thad Allen3 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- SECSEC Form 8-K filed by Artiva Biotherapeutics Inc.8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
- PRArtiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement GrantSAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Thad Huston as Chief Financial Officer. Mr. Huston brings proven expertise in capital allocation, operational execution and global commercialization to support Artiva as it advances AlloNK in autoimmune diseases and continues building an organization positioned for long-term value creation. "We are delighted to welcome Thad to Artiva as he brings strong late-stage development and comme
- INSIDERSEC Form 4 filed by Director Sorg Elaine K.4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sorg Elaine K.3 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- SECSEC Form 8-K filed by Artiva Biotherapeutics Inc.8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
- PRArtiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of DirectorsSAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Elaine Sorg to its Board of Directors. Ms. Sorg brings more than 35 years of executive leadership and commercial experience in the biopharmaceutical industry to Artiva, including leading the commercialization of major immunology therapies such as HUMIRA® (adalimumab) and RINVOQ® (upadacitinib) for rheumatoid arthritis. "We are thrilled to welcome Elaine to Artiva's board at such an imp
- INSIDERSVP, Research and Development Raymon Heather was granted 46,000 shares and covered exercise/tax liability with 1,521 shares, increasing direct ownership by 42% to 151,323 units (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERChief Tech Operations Officer Horan Christopher was granted 117,300 shares and covered exercise/tax liability with 2,187 shares, increasing direct ownership by 62% to 300,452 units (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERCOO, CLO, Secy, Compliance Off Bush Jennifer covered exercise/tax liability with 3,515 shares and was granted 117,300 shares, increasing direct ownership by 49% to 346,710 units (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERChief Medical Officer Banerjee Subhashis was granted 102,000 shares, increasing direct ownership by 204% to 152,000 units (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERPresident and CEO Aslan Fred was granted 366,850 shares and covered exercise/tax liability with 14,600 shares, increasing direct ownership by 29% to 1,562,198 units (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- PRArtiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHLSAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) from February 4 – 7, 2026, in Salt Lake City, Utah highlighting the cost-effectiveness of AlloNK in a community rheumatology practice and continued durability of AlloNK in Non-Hodgkin Lymphoma (NHL). The following abstracts will be presented as poster presentations at the 2026 Tandem Meetings: Post
- PRSeasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines– 25+ years of biotherapeutics leadership, including serving as founding CEO of two NASDAQ-listed companies and securing over $500 million in funding – Expertise in advanced therapeutics development, driving multiple cell and gene therapy product candidates from discovery through to clinical trials COVENTRY, England, Jan. 8, 2026 /PRNewswire/ -- NanoSyrinx, a synthetic biology company developing Nanosyringes™ as a novel platform for targeted intracellular delivery of biologic therapeutics, today announced the appointment of Thomas J. Farrell as Chief Executive Officer and Director. Tom succeeds company founder Joe Healey, who will remain involved in the company, ensuring continuity and o
- INSIDERPresident and CEO Aslan Fred sold $19,122 worth of shares (3,187 units at $6.00), decreasing direct ownership by 0.26% to 1,209,948 units (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERSVP, Research and Development Raymon Heather was granted 67,253 shares, increasing direct ownership by 170% to 106,844 units (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERChief Tech Operations Officer Horan Christopher was granted 107,156 shares, increasing direct ownership by 137% to 185,339 units (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERCOO, CLO, Secy, Compliance Off Bush Jennifer was granted 84,877 shares, increasing direct ownership by 57% to 232,925 units (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
ARTV FAQ
6 questionsWhere does ARTV stock trade?
Artiva Biotherapeutics Inc. (ARTV) is listed on NASDAQ.What sector and industry is ARTV in?
Artiva Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Artiva Biotherapeutics Inc. go public?
Artiva Biotherapeutics Inc. (ARTV) completed its IPO in 2024.What are analysts saying about ARTV?
Artiva Biotherapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1200.00 price target on 2025-06-11. Recent price targets range from $1200.00 to $2300.00.What companies are similar to ARTV?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), BIIB (Biogen Inc.), RVMD (Revolution Medicines Inc.). Compare ARTV side-by-side with any of them on Quantisnow.How can I track ARTV on Quantisnow?
Quantisnow aggregates Artiva Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARTV to receive live email and push alerts on every new disclosure.